Mon Nov 17 03:00:00 UTC 2025: Headline: India Poised to Revolutionize Healthcare with Precision Biotherapeutics, But Challenges Remain

New Delhi, November 17, 2025 – India is eyeing a major leap in healthcare through the adoption of precision biotherapeutics, a cutting-edge field that promises to tailor treatments based on an individual’s unique genetic makeup. This approach, which combines genetic science, molecular biology, and data analytics, aims to correct the root causes of disease, rather than merely managing symptoms.

With non-communicable diseases like diabetes, cardiovascular illness, and cancer accounting for a significant portion of deaths in the country, and its population showcasing remarkable genetic diversity, India presents both a pressing need and a complex testing ground for these novel therapies.

Precision biotherapeutics encompass a range of advanced technologies, including gene editing, mRNA therapeutics, monoclonal antibodies, and AI-driven drug discovery. These tools hold the potential to revolutionize treatment for genetic, metabolic, and oncological diseases, potentially reducing costs and patient suffering in the long run.

The Indian government, through the Department of Biotechnology (DBT) and its funding arm BIRAC, has identified Precision Biotherapeutics as a key focus area. Prominent research institutions like IGIB, NIBMG, and THSTI are actively mapping genetic diversity to understand disease susceptibility across different populations. Several private sector companies, including Biocon Biologics, Dr. Reddy’s Laboratories, and Zydus LifeSciences, are also investing in this area.

However, significant challenges remain. India currently lacks a comprehensive regulatory framework for gene and cell therapies, hindering the development and deployment of these treatments. Limited local manufacturing capacity and the high cost of precision drugs pose significant barriers to accessibility, potentially exacerbating healthcare inequalities.

Experts warn that without addressing these issues, India risks falling behind other nations, such as the United States, the European Union, China, Japan, and Singapore, who are already making significant strides in the field.

To fully harness the potential of precision biotherapeutics, India needs to:

  • Establish a dedicated regulatory framework for gene and cell therapy approvals.
  • Enact a biobanking law that protects privacy and promotes research.
  • Integrate precision medicine into public health through cost-sharing models.
  • Establish national bioethics committees to oversee the ethical use of genetic data.

The global precision medicine market is projected to exceed $22 billion by 2027, presenting India with a significant economic opportunity. By addressing the challenges and fostering innovation in this field, India could establish itself as a global hub for affordable precision therapies, while simultaneously improving the health and well-being of its citizens.

Read More